Mesenchymal Stem Cell-Derived Exosomes For Covid-19 Therapy, Preclinical And Clinical Evidence

12Citations
Citations of this article
27Readers
Mendeley users who have this article in their library.

Abstract

Since the emergence of the novel coronavirus, named COVID-19, researchers are looking for a treatment to stop the evastating pandemic. During these efforts, mesenchymal stem cells (MSCs), the potential next generation of therapeutic methods with wide application for diseases, have successfully controlled cytokine storm following the virus infection. However, the use of MSCs has been limited due to the ethical issues, immunogenicity, and genetic modifications. Therefore, exosomes were introduced as a suitable substitute for the MSCs. In the case of COVID-19 treatment, both MSCs and several preclinical and clinical studies of exosomes for COVID-19 treatment.

Cite

CITATION STYLE

APA

Kiaie, N., Ghanavati, S. P. M., Miremadi, S. S., Hadipour, A., & Aghdam, R. M. (2021). Mesenchymal Stem Cell-Derived Exosomes For Covid-19 Therapy, Preclinical And Clinical Evidence. International Journal of Stem Cells, 14(3), 252–261. https://doi.org/10.15283/IJSC20182

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free